Consultant Psychiatrist Dr. David Erritzoe discusses our Phase IIa Study

Dr. David Erritzoe, Consultant Psychiatrist & Chief Investigator of Small Pharma’s SPL026 Phase I/IIa Study, shares his thoughts on our latest results exploring a short-duration psychedelic for depression, and why this is exciting for the field of psychiatry.

David, PhD, is a Clinical Director and Deputy Head in Centre for Psychedelic Research under the Division of Psychiatry at Imperial College London.

About Small Pharma

We’re a biotechnology company researching and developing short-acting psychedelics with supportive therapy for mental health conditions.

Register for Company Updates

    Corporate Presentation

    Follow us: